Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

• Status: Terminated
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Antibodies, Monoclonal; Exemestane; Fulvestrant; Hormones

Criteria

Inclusion Criteria:

• Postmenopausal women with a diagnosis of hormone receptor positive advanced breast cancer

• HbA1c <5.7%

Exclusion Criteria:

• Previous treatment for advanced disease